Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)
Summary of the evidence on antimicrobial prescribing: delafloxacin
Search results
4 results
-
-
COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)
ES34 Product overview The content of this evidence summary was up to date in January 2021. New evidence may have been
-
Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
-
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
ES33 Product overview The content of this evidence summary was up to date in February 2021. New evidence may have been